Drug Interaction Report

ADJUST DOSING INTERVAL: Iron chelators may decrease the effectiveness of betibeglogene autotemcel. The mechanism has not been established. Hematopoietic stem cell (HSC) mobilization followed by apheresis to obtain CD34+ cells is required for betibeglogene autotemcel manufacturing. Once the correct dose of betibeglogene autotemcel has been stored at the treatment facility and the availability of the back-up collection is confirmed, full myeloablative conditioning must be administered at least 48 hours before infusion of betibeglogene autotemcel. No data are currently available for this interaction.

MANAGEMENT: According to the manufacturer, iron chelators should be avoided for at least 7 days prior to initiation of myeloablative conditioning. After betibeglogene autotemcel infusion, use of myelosuppressive iron chelators should be avoided for 6 months. Non-myelosuppressive iron chelators may be considered if iron chelation is needed within 6 months after betibeglogene autotemcel infusion.

ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.

MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.